Kite Pharma

Kite Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. This is done using engineered autologous cell therapy (eACT). The engineered T cells are designed to recognize and destroy cancer cells. Kite anticipates potential launch and commercialization of its first lead product (KTE-C19) in 2017.
Company Growth (employees)
Santa Monica, US
Size (employees)
447 (est)
Kite Pharma was founded in 2009 and is headquartered in Santa Monica, US

Kite Pharma Office Locations

Kite Pharma has offices in Santa Monica, El Segundo, Seattle, New York and in 31 other locations
Santa Monica, US (HQ)
2225 Colorado Ave, Ca 90404, Usa

Kite Pharma Data and Metrics

Kite Pharma Financial Metrics

Kite Pharma's revenue was reported to be $22.2 m in FY, 2016 which is a 28% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

22.2 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(267.1 m)

EBIT (FY, 2016)

(273.2 m)

Market capitalization (26-May-2017)

4.1 b

Closing share price (26-May-2017)


Cash (31-Dec-2016)

114.6 m
Kite Pharma's current market capitalization is $4.1 b.
Numbers are in $, USDFY, 2015FY, 2016


17.3 m22.2 m

Revenue growth, %


R&D expense

76.4 m197.9 m

General and administrative expense

44.2 m97.4 m

Operating expense total

120.6 m295.4 m


(103.3 m)(273.2 m)

EBIT margin, %


Interest expense

(658 k)(13 k)

Interest income

1.8 m3.6 m

Pre tax profit

(270 m)

Net Income

(101.7 m)(267.1 m)
Numbers are in $, USDFY, 2014FY, 2015FY, 2016


392.8 m114.6 m


286 k16.4 m13 m

Current Assets

631.1 m427.4 m


30.1 m44.4 m


25.4 m24.5 m

Total Assets

708 m524.3 m

Accounts Payable

8 m10.7 m

Current Liabilities

36.2 m55.1 m

Additional Paid-in Capital

775.6 m855.6 m

Retained Earnings

(159.7 m)(426.7 m)

Total Equity

615.8 m428 m

Financial Leverage

1.1 x1.2 x
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Net Income

(101.7 m)(267.1 m)

Depreciation and Amortization

4.6 m10.6 m


1.3 m(14.8 m)3.3 m

Accounts Payable

2.3 m4.5 m2.3 m

Cash From Operating Activities

(16.1 m)(168.9 m)

Purchases of PP&E

(26.6 m)(20.1 m)

Cash From Investing Activities

(108.1 m)(112.9 m)

Cash From Financing Activities

307.7 m3.7 m

Interest Paid

2 k13 k
Y, 2016

Financial Leverage

1.2 x

Kite Pharma Market Value History

Kite Pharma Job Categories

Kite Pharma Online and Social Media Presence

Kite Pharma News and Updates

Kite Pharma Company Life and Culture

You may also be interested in